A new drug for blood cancer from Bristol-Myers Squibb and AbbVie is on the fast track to FDA approval, winning a priority review to treat multiple myeloma.
The market for multiple myeloma drugs is poised for expansion, in part thanks to a globally aging population and improved diagnostic techniques. But new meds are doing their fair share, too, and they'll help push the market's value to nearly $9 billion in 2021, a new report says.
Takeda's top oncology prospect is moving toward approval in the European Union, as continental regulators have accepted the company's application and promised a shortened review period for the blood cancer treatment.
Makers of multiple myeloma drugs are vying for position in a space that's heating up, pointing to promising survival data to help their drugs gain ground. But if they tweaked their marketing strategies, they could have an easier time.
Drugmakers point to promising data for their new multiple myeloma meds, showing that they could tack years onto patients' lives. But for pharma to get the most bang for its buck it should rethink its marketing strategies, according to a study from consulting firm ZS Associates.
Japanese drugmaker Takeda is angling to win FDA approval for its lead cancer asset, an oral treatment for blood malignancies that is key to the company's future in oncology.
After scoring FDA approval earlier this year, Novartis' multiple myeloma med Farydak (panobinostat) is picking up steam across the pond, snagging the European Medicines Agency's (EMA) recommendation for patients with advanced forms of the disease.
MorphoSys has released an early look at data from a Phase I/IIa trial of multiple myeloma drug MOR202. While the results are free from major red flags, the publication of Phase II data on Genmab and Johnson & Johnson's rival anti-CD38 drug just days earlier showed the scale of the task now facing MorphoSys.
It was Johnson & Johnson's turn to take center stage at ASCO Saturday morning, fleshing out the promising data that it accumulated in a Phase II study of daratumumab for treatment-resistant multiple myeloma.
The multiple myeloma market already had a couple of meds with third-line nods when the FDA decided to throw a surprise approval into the mix. Can brand-new Farydak from Novartis actually put up a roadblock for Amgen's Kyprolis and Celgene's Pomalyst? That remains to be seen.